Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.. A complete text table follows the diagram.
CRO revenue reaches a half-year record as new capacity and Satsuma investment hold down operating profit despite stronger demand.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| CRO Services | 1 | 14.1B | 95.7% of reported total |
| Medipolis | 1 | 341M | 2.3% of reported total |
| Other operating segments | 1 | 183M | 1.2% of reported total |
| US Asset Management | 1 | 88M | 0.6% of reported total |
| Translational Research | 1 | 28.1M | 0.2% of reported total |
| Other & rounding | 1 | 0 | 0.0% of reported total |
| Revenues From External Customers | 2 | 14.8B | Reported six-month total · ¥14.8B |
| Operating profit | 3 | 49.3M | 0.3% operating margin |
| Operating costs & expenses | 3 | 14.7B | Arithmetic residual to reported operating profit |
| From | To | Value |
|---|---|---|
| CRO Services | Revenues From External Customers | 14.1B |
| Medipolis | Revenues From External Customers | 341M |
| Other operating segments | Revenues From External Customers | 183M |
| US Asset Management | Revenues From External Customers | 88M |
| Translational Research | Revenues From External Customers | 28.1M |
| Other & rounding | Revenues From External Customers | 0 |
| Revenues From External Customers | Operating profit | 49.3M |
| Revenues From External Customers | Operating costs & expenses | 14.7B |